Comparison of low-dose human menopausal gonadotropin and micronized 17beta-estradiol supplementation in in vitro maturation cycles with thin endometrial lining.
OBJECTIVE
A challenge of in vitro maturation (IVM) treatment in some women is insufficient development of the endometrium prior to embryo transfer.


METHODS
Retrospective study.


METHODS
McGill Reproductive Center, Montreal, Canada.


METHODS
Women with endometrial thickness <6 mm on days 6-10 ultrasound (US) scan of IVM treatment.


METHODS
In the human menopausal gonadotropin (hMG) group, 150 IU/day of hMG was started and in the estradiol group, 6 to 12 mg/day of micronized 17beta-estradiol was initiated. Additional US scans were performed 2 to 3 days apart, until endometrial thickness reached > or =8 mm or a dominant follicle (>10 mm) was identified.


METHODS
Endometrial lining before oocyte retrival.


RESULTS
In both groups endometrial lining significantly thickened following treatment. However, hMG treatment resulted in a higher number of follicles > or =7 mm compared to estradiol (7.4 +/- 4.8 vs. 3.4 +/- 2.5, respectively) and a significantly higher percentage of mature oocytes that were identified on the day of oocyte retrieval (in vivo matured oocytes) (15.1% vs. 10.5%).


CONCLUSIONS
In IVM designated cycles with a thin endometrium both low-dose hMG and micronized 17beta-estradiol supplementation significantly improve endometrial thickness. However, low-dose hMG results in larger follicles and a greater number of in vivo matured oocytes.
Elizur
Shai E
SE
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: shai.elizur@gmail.com.
Son
Weon-Young
WY
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
Yap
Raymond
R
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
Gidoni
Yariv
Y
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
Levin
Dan
D
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
Demirtas
Ezgi
E
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
Tan
Seang-Lin
SL
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill Reproductive Center, McGill University Health Center, Montreal, Quebec, Canada.
D000328:Adult; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004624:Embryo Transfer / Q000379:methods*; D004717:Endometrium / Q000166:cytology / Q000000981:diagnostic imaging* / Q000187:drug effects*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology*; D005307:Fertilization in Vitro / Q000379:methods; D006801:Humans; D008596:Menotropins / Q000494:pharmacology*; D008597:Menstrual Cycle / Q000187:drug effects*; D009865:Oocytes / Q000166:cytology / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014463:Ultrasonography
D005300:Fertility Agents, Female; D004958:Estradiol; D008596:Menotropins